JTX-1484 / Concentra Biosci - LARVOL DELTA

Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells (SITC 2022) - "Ethics Approval Human blood and tumor samples were acquired from commercial providers and from the CHTN and NDRI networks respectively. Specimens were collected under each provider's human subject research institutional review board approved protocols and were fully anonymized or otherwise permanently de-identified to recipient investigators."

IO biomarker • Preclinical • Oncology • FN1

Jounce Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) - "JTX-1484 (LILRB4/ILT3)....JTX-1484 is currently in investigational new drug (IND) enabling activities, with the goal of filing an IND application in 2023."

IND • Oncology

Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress (GlobeNewswire) - "Jounce Therapeutics, Inc...announced poster presentations to be made at upcoming medical meetings. Two preclinical poster presentations will be made at the SITC 2022 Annual Meeting being held in Boston, November 8-12. These will include preclinical data on the JTX-1484 program, which targets LILRB4, and a characterization of the expression and function of LILRB receptors on human immune cells in tumor and blood samples across different cancer types."

Preclinical • Hematological Malignancies • Oncology • Solid Tumor

Jounce Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) - "Vopratelimab (ICOS) and Pimivalimab (PD-1): On track to report clinical data before year end. Jounce plans to submit a clinical data abstract on the SELECT trial, including additional single agent data for pimivalimab, to the ESMO Immuno-Oncology Congress 2022....JTX-1484 (LILRB4/ILT3): Jounce has submitted a preclinical abstract on JTX-1484 for consideration at this year’s annual Society for Immunotherapy of Cancer (SITC) meeting being held from November 9-11 in Boston, MA."

P2 data • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Jounce Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) - "JTX-1484 is the most recent product candidate to emerge from our Translational Science Platform...JTX-1484 is currently in IND-enabling activities, with the goal of filing an IND in 2023."

IND • Oncology